Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer

MELBOURNE, Australia and INDIANAPOLIS, Dec. 19, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it...

Related Keywords

Canada ,United Kingdom ,United States ,Japan ,Belgium ,Australia ,Melbourne ,Victoria ,Switzerland ,Australian ,Alvin Carrie Meinhardt ,Cdx Zircaix ,Brian Shuch ,Christian Behrenbruch ,James Stonecypher ,Kyahn Williamson ,Australian Therapeutic Goods Administration ,Telix Pharmaceuticals Limited ,Telix Group ,Corporate Communications ,Institute Of Urologic Oncology ,Telix Pharmaceuticals ,Telix Pharmaceuticals Limited Disclosure Committee ,Kidney Cancer Research ,Australian Securities Exchange ,Drug Administration ,Health Canada ,Kidney Cancer Program ,Biologics License Application ,Breakthrough Therapy ,Priority Review ,Managing Director ,Chief Development Officer ,Professor Brian Shuch ,Carrie Meinhardt Endowed Chair ,Urologic Oncology ,